Dose-by-dose weight loss in Phase 2 (NEJM) Phase 2 NEJM weight loss by dose, 24 and 48 weeks Dose 1 mg 24 weeks -7.2% 48 weeks -8.7% Dose 4 mg 24 weeks -12.9% 48 weeks -17.5% Dose 8 mg 24 weeks -15.7% 48 weeks -22.8% Dose 12 mg 24 weeks -17.5% 48 weeks -24.2% Dose Placebo 24 weeks -1.6% 48 weeks -2.1% Source: Jastreboff et al., NEJM 2023
Although real-world flexibility can benefit some patients, it should not replace evidence-based protocols entirely
Among the 12mg group, 58.6% achieved 25% or greater weight loss, 39.4% achieved 30% or greater, and 23.7% achieved 35% or greater
Dosing frequency and administration preferences significantly impact adherence and patient satisfaction
Itll feel slow sometimes but just keep doing the little things that you can, little walks etc add up
Does health insurance cover them